| Athanasios Tournas, MD | |
|
425 Guy Park Ave, Suite 100, Amsterdam, NY 12010-1043 | |
| (518) 770-7830 | |
| (518) 770-7805 |
| Full Name | Athanasios Tournas |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 18 Years |
| Location | 425 Guy Park Ave, Amsterdam, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184905697 | NPI | - | NPPES |
| 0101249529 | Other | VA | STATE LICENSE |
| 268672 | Other | NY | STATE LICENSE |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Mary's Healthcare | Amsterdam, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St. Mary's Healthcare | 7618960709 | 79 |
News Archive
David H. Fater, CEO of Vicor Technologies, Inc., today announced that on July 23, 2009, the Australian Patent Office issued it a Deed of Letters Patent for its altered state physiology drug development platform. Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i® nonlinear algorithm and software to stratify patients at risk of sudden cardiac death and trauma victims in need of lifesaving intervention.
Today's headlines feature reports about new government projections for the nation's health care spending and the latest from the campaign trail.
The humble yeast has revealed the molecular workings of an anti-cancer drug that stops the growth and spread of tumours in humans by starving their blood supply.
Creation of a genetic risk score comprised of multiple genetic markers associated with cardiovascular disease (CVD) was not associated with significant improvement in CVD risk prediction in a study that included more than 19,000 women, according to a study in the February 17 issue of JAMA.
› Verified 3 days ago
| Entity Name | St. Mary's Healthcare |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518926401 PECOS PAC ID: 7618960709 Enrollment ID: O20040405001628 |
News Archive
David H. Fater, CEO of Vicor Technologies, Inc., today announced that on July 23, 2009, the Australian Patent Office issued it a Deed of Letters Patent for its altered state physiology drug development platform. Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i® nonlinear algorithm and software to stratify patients at risk of sudden cardiac death and trauma victims in need of lifesaving intervention.
Today's headlines feature reports about new government projections for the nation's health care spending and the latest from the campaign trail.
The humble yeast has revealed the molecular workings of an anti-cancer drug that stops the growth and spread of tumours in humans by starving their blood supply.
Creation of a genetic risk score comprised of multiple genetic markers associated with cardiovascular disease (CVD) was not associated with significant improvement in CVD risk prediction in a study that included more than 19,000 women, according to a study in the February 17 issue of JAMA.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Athanasios Tournas, MD 425 Guy Park Ave, Suite 100, Amsterdam, NY 12010-1043 Ph: (518) 770-7830 | Athanasios Tournas, MD 425 Guy Park Ave, Suite 100, Amsterdam, NY 12010-1043 Ph: (518) 770-7830 |
News Archive
David H. Fater, CEO of Vicor Technologies, Inc., today announced that on July 23, 2009, the Australian Patent Office issued it a Deed of Letters Patent for its altered state physiology drug development platform. Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i® nonlinear algorithm and software to stratify patients at risk of sudden cardiac death and trauma victims in need of lifesaving intervention.
Today's headlines feature reports about new government projections for the nation's health care spending and the latest from the campaign trail.
The humble yeast has revealed the molecular workings of an anti-cancer drug that stops the growth and spread of tumours in humans by starving their blood supply.
Creation of a genetic risk score comprised of multiple genetic markers associated with cardiovascular disease (CVD) was not associated with significant improvement in CVD risk prediction in a study that included more than 19,000 women, according to a study in the February 17 issue of JAMA.
› Verified 3 days ago
Karen Lizhong Tan, MD Otolaryngology Medicare: May Accept Medicare Assignments Practice Location: 5010 State Highway 30, Suite 204, Amsterdam, NY 12010 Phone: 518-842-8185 Fax: 518-842-8189 |